Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:ASND OTCMKTS:EVTCY NASDAQ:MRTX NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$37.23-1.1%$29.86$9.57▼$40.29$5.16B1.132.05 million shs436,493 shsASNDAscendis Pharma A/S$201.32-0.7%$199.67$118.03▼$216.45$12.42B0.41480,280 shs49,841 shsEVTCYEvotec$3.93-2.0%$3.68$14.22▼$26.57$1.30B0.982,407 shs41,073 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AUTHRUnited Therapeutics$422.93+0.3%$393.00$266.98▼$459.48$19.08B0.66590,916 shs92,986 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-1.05%-1.47%+17.41%+131.43%+84.64%ASNDAscendis Pharma A/S+1.05%-2.13%+3.20%+20.43%+57.05%EVTCYEvotec+2.30%+3.35%+10.16%+4.97%+26.50%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%UTHRUnited Therapeutics-0.21%-2.44%+1.67%+37.61%+13.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$37.23-1.1%$29.86$9.57▼$40.29$5.16B1.132.05 million shs436,493 shsASNDAscendis Pharma A/S$201.32-0.7%$199.67$118.03▼$216.45$12.42B0.41480,280 shs49,841 shsEVTCYEvotec$3.93-2.0%$3.68$14.22▼$26.57$1.30B0.982,407 shs41,073 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AUTHRUnited Therapeutics$422.93+0.3%$393.00$266.98▼$459.48$19.08B0.66590,916 shs92,986 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-1.05%-1.47%+17.41%+131.43%+84.64%ASNDAscendis Pharma A/S+1.05%-2.13%+3.20%+20.43%+57.05%EVTCYEvotec+2.30%+3.35%+10.16%+4.97%+26.50%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%UTHRUnited Therapeutics-0.21%-2.44%+1.67%+37.61%+13.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1414.65% UpsideASNDAscendis Pharma A/S 2.94Moderate Buy$249.8023.24% UpsideEVTCYEvotec 0.00N/AN/AN/AMRTXMirati Therapeutics 0.00N/AN/AN/AUTHRUnited Therapeutics 2.57Moderate Buy$461.629.48% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, MRTX, EVTCY, ASND, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$414.0010/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$328.00 ➝ $435.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.0010/8/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025UTHRUnited TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/29/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$560.00 ➝ $580.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,465.56N/AN/A$1.54 per share24.44ASNDAscendis Pharma A/S$393.54M31.77N/AN/A($1.88) per share-107.82EVTCYEvotec$572.16M2.31$0.04 per share105.53$2.52 per share1.59MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39UTHRUnited Therapeutics$2.88B6.61$28.34 per share14.88$144.34 per share2.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A844.58N/A-54.94%N/A-24.31%11/13/2025 (Estimated)EVTCYEvotec$7.14M$0.419.78∞N/A20.85%16.02%7.81%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/AUTHRUnited Therapeutics$1.20B$25.6216.4615.344.6040.36%18.73%16.49%10/29/2025 (Estimated)Latest UTHR, MRTX, EVTCY, ASND, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A10/29/2025Q3 2025UTHRUnited Therapeutics$6.75N/AN/AN/A$812.87 millionN/A8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87ASNDAscendis Pharma A/SN/A1.020.69EVTCYEvotec0.532.572.50MRTXMirati TherapeuticsN/A7.547.40UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%ASNDAscendis Pharma A/SN/AEVTCYEvotecN/AMRTXMirati TherapeuticsN/AUTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%ASNDAscendis Pharma A/S40.00%EVTCYEvotecN/AMRTXMirati Therapeutics3.26%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR, MRTX, EVTCY, ASND, and ARWR HeadlinesRecent News About These CompaniesUnited Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOctober 22 at 11:06 AM | zacks.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowOctober 22 at 9:50 AM | zacks.comTFB Advisors LLC Raises Stock Position in United Therapeutics Corporation $UTHROctober 22 at 8:19 AM | marketbeat.comNordea Investment Management AB Acquires 3,664 Shares of United Therapeutics Corporation $UTHROctober 22 at 4:21 AM | marketbeat.comUnited Therapeutics (UTHR) Expected to Announce Earnings on WednesdayOctober 22 at 4:06 AM | marketbeat.comIf You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much TodayOctober 21 at 10:28 PM | benzinga.comUnited Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 SharesOctober 21 at 4:49 PM | marketbeat.comChevy Chase Trust Holdings LLC Acquires 5,393 Shares of United Therapeutics Corporation $UTHROctober 21 at 4:17 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesOctober 21 at 4:02 AM | insidertrades.comCwm LLC Boosts Stake in United Therapeutics Corporation $UTHROctober 21 at 3:24 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,698,360.00 in StockOctober 20 at 7:40 PM | marketbeat.comPaul Mahon Sells 11,000 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 20 at 10:43 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Coverage Initiated at Wells Fargo & CompanyOctober 20 at 8:27 AM | marketbeat.comAllianz Asset Management GmbH Sells 3,486 Shares of United Therapeutics Corporation $UTHROctober 20 at 5:08 AM | marketbeat.comVIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in United Therapeutics Corporation $UTHROctober 19, 2025 | marketbeat.comEnvestnet Portfolio Solutions Inc. Boosts Stake in United Therapeutics Corporation $UTHROctober 19, 2025 | marketbeat.comGenerali Asset Management SPA SGR Has $1.79 Million Stock Holdings in United Therapeutics Corporation $UTHROctober 18, 2025 | marketbeat.comTD Asset Management Inc Sells 15,633 Shares of United Therapeutics Corporation $UTHROctober 17, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Raises Stake in United Therapeutics Corporation $UTHROctober 17, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesOctober 16, 2025 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of StockOctober 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR, MRTX, EVTCY, ASND, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$37.23 -0.40 (-1.06%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Ascendis Pharma A/S NASDAQ:ASND$201.32 -1.38 (-0.68%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Evotec OTCMKTS:EVTCY$3.93 -0.08 (-2.00%) As of 10/22/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$422.93 +1.29 (+0.31%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
